Paramount/WBD merger conditions give the public "virtually nothing," judge is told

Free-speech and media advocacy groups urged a federal judge to reject California's settlement with Paramount Skydance, which would allow its $111 billion merger with Warner Bros. Discovery to proceed. The merger had previously been delayed after Judge Araceli Martínez-Olguín found it was likely to substantially reduce competition and violate antitrust law. Approval of the multistate settlement remains subject to the judge's decision, leaving a material regulatory and litigation risk over the transaction.

Analysis

The relevant asset is the merger-arbitrage spread, not the standalone media thesis. Judicial rejection or a demand for materially stronger remedies would reintroduce a prolonged litigation timetable, raising financing, integration-delay, and talent-retention costs; that is disproportionately negative for PSKY if it is the acquirer and only partially offsets the premium embedded in WBD. Advocacy-group intervention is unlikely by itself to determine the outcome, but it increases the probability that the court treats the settlement as inadequate rather than deferring to the state parties.

Over the next days to weeks, the catalyst is the court’s treatment of the settlement and any required evidentiary process. A clean approval should compress the WBD deal spread and reduce PSKY’s regulatory overhang, while a rejection could produce a sharp WBD drawdown toward standalone value and PSKY relief if the market views the transaction as financially dilutive. Over 6-18 months, the core risk remains that remedies preserving nominal content access do not solve bargaining-power concentration in advertising, carriage, and streaming rights; that creates follow-on conduct-regulation risk even if closing occurs.

Consensus may be assigning too much weight to the states’ settlement as a terminal regulatory event. The more important uncertainty is whether the court imposes an independent competitive-harm standard and whether federal or private challengers can extend the closing timeline. Without verified consideration terms, financing commitments, termination fee, and current spread, a directional merger-arbitrage recommendation is premature; the appropriate posture is conditional rather than outright exposure.

Key Decisions for Investors

• Do not initiate a naked long WBD merger-arbitrage position until the cash/stock consideration, implied spread, outside date, and termination fee are verified. Set an alert for court approval: if the annualized gross spread remains above 15% after a clean approval, buy WBD for closing; exit if the court requires a new remedy package or extends review beyond 60 days.
• For existing WBD exposure, hedge event risk over the ruling window with short-dated WBD puts or a put spread sized to the estimated gap between current price and independently derived standalone value. This is preferable to reducing all exposure when approval probability remains uncertain but downside is discontinuous.
• Use a market-neutral relative-value framework rather than shorting PSKY outright: long WBD / short PSKY only if published terms show WBD’s consideration is fixed and PSKY is economically bearing the incremental regulatory-delay cost. Cover immediately on settlement approval if PSKY’s funding plan is fully committed and no divestiture or conduct remedy is added.
• Watch PSKY credit spreads and any revision to financing disclosures over the next 1-3 months. A material widening in PSKY debt spreads or higher funding-cost guidance would signal that delay is becoming an economic, not merely legal, issue and would strengthen the case for reducing PSKY exposure.